Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury

Does Vascular Occlusion in Liver Resections Predispose to Recurrence of Malignancy in the Liver Remnant Due to Ischemia/Reperfusion Injury?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04257240

Acronym

annie-liver

Enrollment

230

Registered

2020-02-05

Start date

2000-01-01

Completion date

2012-12-31

Last updated

2020-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Recurrence, Ischemic Reperfusion Injury, Liver Cancer, Liver Injury, Malignancy

Keywords

ischemia reperfusion injury, liver surgery, cancer recurrence, malignancy, hepatectomy

Brief summary

Severe ischemic changes of the liver remnant after hepatectomy could expedite tumor recurrence on the residual liver. Our study aimed at assessing the effect of warm ischemic/reperfusion (I/R) injuries on surgery-to-local recurrence interval and patient overall survival, during major hepatectomies under inflow and outflow vascular control.

Detailed description

One hundred and eighteen patients were subjected to liver resection under total inflow and outflow vascular clamping and were assigned as study group. These individuals were retrospectively matched to 112 counterparts, who underwent liver surgery applying inflow and outflow vascular clamping only of the segment harboring the tumor, sparing the liver remnant from any I/R injury (control group). The two cohorts were compared regarding recurrence-free survival and overall survival.

Interventions

PROCEDUREselective hepatic vascular exclusion

major hepatectomy with vascular control of blood inflow and outflow of the whole liver

PROCEDUREsemielective hepatic vascular exclusion

major liver resection by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Adult patients * American Society of Anesthesiologists (ASA) distribution I to III * Patients scheduled for major liver resection (≥3 segments)

Exclusion criteria

* patients with extrahepatic disease * patients with metastatic liver tumors

Design outcomes

Primary

Measure	Time frame	Description
time to death	from time of operation until time of death, assessed up to 20 years	overall survival
time to malignant recurrence	from time of operation until time of malignant recurrence, assessed up to 15 years	recurrence-free survival

Secondary

Measure	Time frame	Description
aspartate aminotrasferase (AST) levels	second postoperative day	aspartate aminotransferase levels

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026